@ARTICLE{
author={Mateos Maria-Victoria,Szarejko Monika,Bila Jelena S,Schjesvold Fredrik,Spicka Ivan,Maisnar Vladimir,Jurczyszyn Artur,Grudeva-Popova Zhanet,Hajek Roman,Usenko Hanna,Thuresson Marcus,Norin Stefan,Jarefors Sara,Richardson Paul,Pour Ludek},
year={2023},
title={Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy},
journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
volume={23},
number={},
pages={S200-S201},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Dimopoulos Meletios Athanasios,Terpos Evangelos,Boccadoro Mario,Delimpasi Sosana,Beksac Meral,Katodritou Eirini,Moreau Philippe,Baldini Luca,Symeonidis Argiris,Bila Jelena S,Oriol Albert,Mateos Maria-Victoria,Einsele Hermann,Orfanidis Ioannis,Kampfenkel Tobias,Liu Weiping,Kosh Michele,NamPhuong Tran,Carson Robin,Sonneveld Pieter},
year={2022},
title={Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study},
journal={BLOOD},
volume={140},
number={},
pages={7272-7274},
document_type={Meeting Abstract},
}